Your Client Is Doing At-Home Ketamine. Here's What to Ask

In a recent consultation group, we'd spent a while on a case involving a client on one of the telehealth ketamine platforms when a newer clinician in the group asked, sincerely, whether she was even allowed to discuss the ketamine with her own client, since she hadn't prescribed it and wasn't trained in it. The question stopped the room, not because it was naive but because nobody had a confident answer. Here was a licensed therapist seeing a client weekly, wondering if the most significant treatment in that client's life was off-limits as a topic.

That confusion is now common enough to deserve its own clinical literacy. And if you search for at-home ketamine therapy safety information, nearly everything you'll find was written by the companies selling it. This post is the other version: what the independent evidence and the regulatory record actually show, what you're allowed to ask (everything), and what to ask first.

The at-home model exists because of a regulatory accident. COVID-era DEA flexibilities allowed controlled substances to be prescribed via telemedicine without an in-person evaluation; an industry assembled itself on top of that allowance, shipping compounded sublingual ketamine to the door with a video intake on the front end. The US ketamine market grew past 1,500 clinics and platforms. What got cut to make the economics work was everything labor-intensive: preparation, real-time monitoring during dosing, structured integration. That wasn't an accident. It was a business model, and I've written before about what it removed.

To be precise about terms: this is ketamine treatment, not ketamine-assisted psychotherapy (KAP). KAP means medicine plus therapy as an integrated protocol. Most at-home platforms ship the medicine and leave the therapy to whoever the client already sees. Often, that's you. Which answers the consultation-group question: you're not just allowed to engage with this treatment, you may be the only clinician positioned to.

In March 2026, STAT published an analysis by Michael Alvear, an independent researcher and patient advocate who reviewed six months of discussion in two large ketamine-patient Reddit communities. Self-selected forum data isn't prevalence data (struggling patients post more, and Alvear says so himself), but as an early-warning signal, the patterns are hard to dismiss:

• Prescribed doses ranging from 50 mg to 800 mg, a sixteen-fold variance across platforms, against the 84 mg ceiling that governs FDA-approved esketamine (Spravato) in monitored clinical settings.
• Monitoring that ends after session one. Most platforms supervise the first dose by video; after that, patients dose alone.
• Patients crowdsourcing their own treatment decisions, adjusting doses based on upvotes and anecdote, and reporting adverse effects to each other (chronic vomiting, bladder pain, blood in urine, frightening dissociative episodes) rather than to anyone with prescribing authority.

Alvear's summary line is the one to keep: these services have created a system where the burden of safety management falls on the patient. Ketamine has genuine addiction potential, and escalating-dose use carries documented bladder and cognitive risks. A monitoring structure that assumes the patient will self-report dose escalation is a structure that has misunderstood dose escalation.

Three things are converging on this industry at once.

1. The legal foundation has an expiration date. The DEA's telemedicine flexibility, the rule that makes remote ketamine prescribing possible at all, is on its fourth temporary extension, expiring December 31, 2026. The DEA has signaled it intends to replace the extensions with a permanent framework. Nobody knows what that framework will require; a meaningful in-person-evaluation requirement would restructure or end the at-home model. If your client's treatment depends on this rule, their treatment has a contingency built into it that nobody has discussed with them.
2. FDA has already warned about the supply. In an October 2023 safety communication, the agency warned patients and providers about compounded ketamine products, oral formulations specifically, citing sedation, dissociation, abuse potential, and bladder symptoms, and noting that at-home use means no provider is present to catch serious outcomes. The warning included a case report of respiratory depression in a patient whose blood level reached roughly twice anesthetic range. The compounding pipeline these platforms run on operates under that standing caution, with industry observers reporting continued regulatory attention since.
3. States are starting to act. The Texas Medical Board has proposed tighter ketamine oversight, including more physician involvement during administration and a ban on in-home use. In the absence of prospective standards, the field is being regulated retroactively, through audits, investigations, and enforcement.

None of this should be read as "at-home ketamine is about to be banned." It should be read as: the model your client is relying on is provisional, and the people profiting from it have not made that clear to them.

You don't need prescribing authority to be the most consistent safety presence in this treatment. You may already be the only clinician who sees this client weekly. Questions worth working into intake or an early check-in, in plain clinical curiosity rather than alarm:

• Who prescribed it, and what did the evaluation involve? A video intake? Any medical history review? Does the prescriber know about prior substance use, cardiovascular issues, or psychosis history?
• What's the dose and frequency now, and what was it at the start? Trajectory matters more than the number. Escalation is the pattern to catch early.
• Is anyone present during sessions? Dosing alone, dissociated, with nobody in the home is the scenario the platforms' marketing photos never show.
• What does the platform's follow-up actually consist of? A monthly questionnaire is not monitoring.
• Does the prescriber know about me, and can I have a release? Coordination across the medical and therapy sides of this treatment usually doesn't exist until someone builds it. Be the someone.
• What's the experience like, and what happens with it afterward? This opens the integration conversation: the part of the protocol the business model removed, and the part you're positioned to restore.

The clinical temptation runs in two directions: gatekeep (treat the disclosure as a problem to shut down) or wave through (treat it as none of your business). Both abandon the client. The defensible middle is harm reduction with full engagement: this person sought out a rapid-acting treatment because they were suffering, the treatment has real evidence behind the medicine and real holes in its delivery, and you are positioned to fill several of those holes (risk awareness, dose-trajectory attention, coordination, integration) without endorsing or opposing the platform. Their treatment shouldn't have to depend on Reddit. For now, for many patients, it does. The clinicians already in the room are the corrective that's actually available.

Yes. Nothing prevents a licensed therapist from discussing a client's ketamine treatment, and you may be the only clinician seeing that client weekly. This is ketamine treatment, not ketamine-assisted psychotherapy; most platforms ship the medicine and leave the therapy to whoever the client already sees. Engaging with it is within your scope, not outside it.

The medicine has real evidence, but the at-home delivery model has documented gaps. Independent reports describe prescribed doses varying up to sixteen-fold and monitoring that often ends after the first session. Ketamine carries addiction potential and bladder and cognitive risks with escalating use, so a model relying on patient self-report of dose escalation is a genuine concern.

Ask who prescribed it and what the evaluation involved, the current dose and frequency versus the starting dose, whether anyone is present during dosing, what the platform's follow-up actually consists of, and whether you can coordinate with the prescriber through a release. Dose trajectory matters more than any single number; escalation is the pattern to catch early.

At-home ketamine prescribing relies on a COVID-era DEA telemedicine flexibility now on its fourth temporary extension, expiring December 31, 2026. The DEA intends to replace it with a permanent framework, and a meaningful in-person-evaluation requirement could restructure or end the at-home model. Clients should know their treatment has this contingency built in.

Peter Addy, PhD, LPC, LMHC is a Portland-based licensed therapist and the founder of Psychedelic Affirming Education, an NBCC-approved continuing education provider for licensed mental health professionals and Oregon Psilocybin Services facilitators. His research background includes work at Yale School of Medicine on psychedelic substances.

If clients on ketamine are showing up in your practice: the Ethical Guidelines For Ketamine Clinicians course (2 CEs) covers scope, consent, and coordination questions exactly like these. Pair it with KAP Suicide Assessment (1 CE) if you're working with the treatment-resistant depression population these platforms serve.